Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
Summary
Nexalin Technology closed the acquisition of PONM, the AI-integrated digital health platform that powers its HALO Clarity and Nexalin NeuroCare programs, and now operates PONM as a wholly owned subsidiary. The purchase secures exclusive software features for AI-enabled remote patient monitoring, treatment-compliance data capture, EHR functionality, virtual-clinic management, and real-time analytics already deployed at UCSD. GreenLight Ventures became a meaningful Nexalin shareholder and strategic partner, and Nexalin will pay $1.3 million in stock consideration issued in tranches tied to market performance. Nexalin says the acquisition strengthens control over its device-plus-software ecosystem to support a planned 160-participant FDA pivotal trial and potential regulatory submission and commercial rollout.